Understand the source comparison
Peptide Recomposition Protocol Comparison
GHRH Monotherapy CJC-1295 (no DAC) + Ipamorelin 1–2x daily (pre-bed, pre-workout) 2–4× baseline during pulses Minimal High. Preserves insulin sensitivity, supports fat loss phases Ghrelin Agonist Monotherapy MK-677 (ibutamoren) Once daily (evening preferred) 1
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- GHRH Monotherapy
- CJC-1295 (no DAC) + Ipamorelin
- 1–2x daily (pre-bed, pre-workout)
- 2–4× baseline during pulses
- Minimal
- High. Preserves insulin sensitivity, supports fat loss phases
- Ghrelin Agonist Monotherapy
- MK-677 (ibutamoren)
- Once daily (evening preferred)
- 1.5–2× baseline sustained
- Significant increase
- Moderate. Appetite makes deficit adherence harder
- Synergistic Stack
- CJC-1295 + Ipamorelin + low-dose MK-677
- CJC 2x/week, Ipa daily, MK nightly
- 3–5× baseline with sustained IGF-1
- Moderate
- Very High. Combines pulsatile and sustained elevation
- Recovery-Focused Stack
- BPC-157 + TB-500 + GHRH analog
- BPC/TB daily, GHRH 2x/week
- 2–3× baseline
- None
- High for injury-prone individuals or high training volume
- Professional Assessment
- For pure recomposition (fat loss + muscle gain simultaneously), the synergistic GHRH + ghrelin stack outperforms monotherapy by maintaining anabolic signalling during caloric deficits without excessive appetite disruption. Recovery peptides amplify training volume capacity, which indirectly drives recomposition through increased stimulus.